InVivo Therapeutics to Present at Cell & Gene Meeting on the Mesa
InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, will
present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla,
California. The company’s presentation will be on October 6 at 4:00 PM (PDT). A live webcast will be available at http://www.meetingonthemesa.com/webcast/ and will also be published on the Alliance for Regenerative Medicine
(ARM)’s website shortly after the event.
Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day
conference featuring three distinct parts: the program’s two-day Partnering Forum, a public forum lecture, and a full-day
scientific symposium.
Dr. Ulich said, “We look forward to sharing the latest news about our Neuro-Spinal Scaffold™ and Bioengineered Neural
Trails™ with the community.”
This year’s event is expected to attract more than 800 attendees, including senior executives from leading cell therapy, gene
therapy, and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research
institutions, patient foundations, disease philanthropies, and life science media.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on
treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D.,
Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who
now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered
in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
InVivo Therapeutics
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005085/en/